News
A promising new cancer technology from NIH could help improve how liver cancer is diagnosed and treated. Liver cancer, particularly hepatocellular carcinoma (HCC), remains one of the deadliest cancers worldwide, and better treatment options are urgently needed. NIH inventors have developed two fully
Register to attend a free webinar to assess co-developing an NCI technology. Attendees will learn about new antibodies developed at the National Cancer Institute in the laboratory of David Fitzgerald, Ph.D. Dr. Fitzgerald and his team established that using one of the antibodies, 40H3, as an
Inventors at the National Human Genome Research Institute (NHGRI) discovered that N-acetylmannosamine (ManNAc) can be used for therapeutic purposes. ManNAc therapy given orally shows long-term safety and biochemical efficacy. ManNAc is a small uncharged physiological molecule that crosses membranes
NIH has 1,200 scientists in the Intramural Research Program who research and develop new drugs, vaccines, methods, and other products to better public health. These scientists become inventors when their research results in a licensable material or product. The NIH Record sat down with Dr. Niraj